Ahmad Doroudian's guest appearances

Ahmad Doroudian

Psychedelics Today

The Exchange for Entrepreneurs™ Podcast 

Conscious Conversations

Adriana Kertzer

Trevor Koverko

Ryan Zurrer

Michael Pollan

Richard Grossman

David Krantz

Becca Segall Tarnas

Renn Butler

Joe Moore

Adam Strauss

Lynn Marie Morski

Richard Graham

Rick Doblin

Harvey Schwartz

Daniel Pinchbeck

OwlTail

Abid Nazeer

In this week's Solidarity Fridays episode, Joe and David speak with CEO &amp; Director of BetterLife Pharma, Ahmad Doroudian, about 2-Bromo-LSD, and then David interviews Chief Medical Officer at Wesana Health, Abid Nazeer.  www.psychedelicstoday.com

In this week's Solidarity Fridays episode, Joe and David speak with CEO &amp; Director of BetterLife Pharma, Ahmad Doroudian, about 2-Bromo-LSD, and then David interviews Chief Medical Officer at Wesana Health, Abid Nazeer.  <a href="http://www.psychedelicstoday.com" rel="nofollow" target="_blank">www.psychedelicstoday.com</a>

PTSF85 – Ahmad Doroudian, Ph.D. of BetterLife Pharma and Dr. Abid Nazeer of Wesana Health

BetterLife Pharma CEO Ahmad Doroudian (PhD) sits down with TCF co-founding partner Henri Sant-Cassia for our latest edition of Conscious Conversations as we discuss unique value proposition, psychedelic investment, and how the future of psychedelic medicine is looking to shape up. BetterLife is focused on developing second generation psychedelic compounds, and nutraceuticals; addressing unmet needs within mental health, wellness and anti-aging industries without the hallucinogenic effects.

<a href="https://abetterlifepharma.com/" rel="noopener nofollow" target="_blank">BetterLife Pharma</a> CEO Ahmad Doroudian (PhD) sits down with TCF co-founding partner Henri Sant-Cassia for our latest edition of Conscious Conversations as we discuss unique value proposition, psychedelic investment, and how the future of psychedelic medicine is looking to shape up. BetterLife is focused on developing second generation psychedelic compounds, and nutraceuticals; addressing unmet needs within mental health, wellness and anti-aging industries without the hallucinogenic effects.

Conscious Conversations - Ahmad Doroudian

Dr. Ahmad Doroudian on the Potential of a COVID-19 Treatment, Not a Cure | #HashtagFinanceThe CSE's Barrington Miller chats with Dr. Ahmad Doroudian, CEO of BetterLife Pharma Inc. (CSE:BETR), about BetterLife’s ambitions to advance on the AP-003 clinical trial programs of Altum Pharmaceuticals Inc., which includes a therapeutic pipeline consisting of three products, including AP-003, a patent-pending interferon a2b (IFNa2b) inhalation formulation. Recent studies in China and the UK have provided data that suggest the therapeutic efficacy of interferon-based treatments for COVID-19.Here's an overview of what’s covered in this edition of the #HashtagFinance podcast:3:47 - What BetterLife is doing about COVID-19.7:01 - How early their product can be used, and if it can be used for prevention.9:32 - What BetterLife was working on before the COVID-19 pandemic.11:32 - The differentiators between BetterLife and other companies developing COVID-19 treatments.15:38 - Taking the treatment approach, instead of the cure approach, to COVID-19, similar to HIV.19:58 - Phase II clinical trials, and what that means for an investor.BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. Through its wholly owned subsidiary, BLife Therapeutics Inc., BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.Related linkshttps://blifetherapeutics.com/https://thecse.com/en/listings/life-sciences/betterlife-pharma-inc

Dr. Ahmad Doroudian on the Potential of a COVID-19 Treatment, Not a Cure | #HashtagFinanceThe CSE's Barrington Miller chats with Dr. Ahmad Doroudian, CEO of BetterLife Pharma Inc. (CSE:BETR), about BetterLife’s ambitions to advance on the AP-003 clinical trial programs of Altum Pharmaceuticals Inc., which includes a therapeutic pipeline consisting of three products, including AP-003, a patent-pending interferon a2b (IFNa2b) inhalation formulation. Recent studies in China and the UK have provided data that suggest the therapeutic efficacy of interferon-based treatments for COVID-19.Here's an overview of what’s covered in this edition of the #HashtagFinance podcast:3:47 - What BetterLife is doing about COVID-19.7:01 - How early their product can be used, and if it can be used for prevention.9:32 - What BetterLife was working on before the COVID-19 pandemic.11:32 - The differentiators between BetterLife and other companies developing COVID-19 treatments.15:38 - Taking the treatment approach, instead of the cure approach, to COVID-19, similar to HIV.19:58 - Phase II clinical trials, and what that means for an investor.BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. Through its wholly owned subsidiary, BLife Therapeutics Inc., BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.Related links<a href="https://blifetherapeutics.com/" rel="nofollow" target="_blank">https://blifetherapeutics.com/</a><a href="https://thecse.com/en/listings/life-sciences/betterlife-pharma-inc" rel="nofollow" target="_blank">https://thecse.com/en/listings/life-sciences/betterlife-pharma-inc</a>

Dr. Ahmad Doroudian on the Potential of a COVID-19 Treatment | #HashtagFinance